Chen Xuerui, Liu Bingbing, Tong Rongliang, Zhan Lin, Yin Xuelian, Luo Xin, Huang Yanan, Zhang Junfeng, He Wen, Wang Yanli
Tumor Precision Targeting Research Center, School of Medicine & School of Environmental and Chemical Engineering, Shanghai University, Shanghai 200444, China.
Department of Chemistry, Zhejiang University, Hangzhou 310027, China.
Biomater Sci. 2021 Feb 9;9(3):590-625. doi: 10.1039/d0bm01617a.
Nanoparticle-based therapeutic and detectable modalities can augment anticancer efficiency, holding potential in capable target and suppressive metastases post administration. However, the individual discrepancies of the current "one-size-fits-all" strategies for anticancer nanotherapeutics have heralded the need for "personalized therapy". Benefiting from the special inherency of various cells, diverse cell membrane-coated nanoparticles (CMCNs) were established on a patient-by-patient basis, which would facilitate the personalized treatment of individual cancer patients. CMCNs in a complex microenvironment can evade the immune system and target homologous tumors with a suppressed immune response, as well as a prolonged circulation time, consequently increasing the drug accumulation at the tumor site and anticancer therapeutic efficacy. This review focuses on the emerging strategies and advances of CMCNs to synergistically integrate the merit of source cells with nanoparticulate delivery systems for the orchestration of personalized anticancer nanotherapeutics, thus discussing their rationalities in facilitating chemotherapy, imaging, immunotherapy, phototherapy, radiotherapy, sonodynamic, magnetocaloric, chemodynamic and gene therapy. Furthermore, the mechanism, challenges and opportunities of CMCNs in personalized anticancer therapy were highlighted to further boost cooperation from different fields, including materials science, chemistry, medicine, pharmacy and biology for the lab-to-clinic translation of CMCNs combined with the individual advantages of source cells and nanotherapeutics.
基于纳米颗粒的治疗和检测方式可以提高抗癌效率，在给药后具有靶向和抑制转移的潜力。然而，当前抗癌纳米疗法“一刀切”策略的个体差异预示着需要“个性化治疗”。得益于各种细胞的特殊内在特性，逐例构建了多种细胞膜包被纳米颗粒（CMCNs），这将有助于对个体癌症患者进行个性化治疗。在复杂微环境中的CMCNs可以逃避免疫系统，以抑制的免疫反应靶向同源肿瘤，同时延长循环时间，从而增加药物在肿瘤部位的积累和抗癌治疗效果。本综述重点关注CMCNs的新兴策略和进展，以将源细胞的优点与纳米颗粒递送系统协同整合，用于精心设计个性化抗癌纳米疗法，从而讨论它们在促进化疗、成像、免疫疗法、光疗、放疗、声动力、磁热、化学动力和基因治疗方面的合理性。此外，还强调了CMCNs在个性化抗癌治疗中的机制、挑战和机遇，以进一步促进不同领域（包括材料科学、化学、医学、药学和生物学）的合作，实现CMCNs从实验室到临床的转化，并结合源细胞和纳米疗法的个体优势。
Zotero 插件